Trinity Biotech buys Bartels for $9.3 million:
This article was originally published in Clinica
Executive Summary
Trinity Biotech has bought the assets and goodwill of Intracel division Bartels, a manufacturer of cell dependent infectious agent diagnostics, for $9.3 million in stock and cash. The product range includes antigen detection kits for herpes simplex virus, as well as respiratory viruses, including A and B types flu, para-influenza viruses 1, 2 and 3 and respiratory syncitial virus. It also manufactures and sells infectious disease confirmatory reagents. Dublin, Ireland-based Trinity Biotech says the acquisition of Bartels, based in Issaquah, Washington, will strengthen its distribution capabilities in the US.